John Cerio
Human Resources Officer at ORCHARD THERAPEUTICS PLC
John Cerio active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ORCHARD THERAPEUTICS PLC | Human Resources Officer | - | - |
Career history of John Cerio
Former positions of John Cerio
| Companies | Position | Start | End |
|---|---|---|---|
PerkinElmer Life Sciences, Inc.
 PerkinElmer Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology PerkinElmer Life Sciences, Inc. Provided drug discovery, life science research and clinical screening services. It was headquartered in Boston, MA. | Human Resources Officer | - | - |
| BRISTOL-MYERS SQUIBB COMPANY | Human Resources Officer | - | - |
| AGENUS INC. | Chief Administrative Officer | 2002-12-31 | - |
| Human Resources Officer | 2002-12-31 | - |
Training of John Cerio
| Cornell University | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Graduate Degree |
Statistics
International
| United States | 6 |
| United Kingdom | 2 |
Operational
| Human Resources Officer | 4 |
| Chief Administrative Officer | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| AGENUS INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private companies | 2 |
|---|---|
PerkinElmer Life Sciences, Inc.
PerkinElmer Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology PerkinElmer Life Sciences, Inc. Provided drug discovery, life science research and clinical screening services. It was headquartered in Boston, MA. | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- John Cerio
- Experience
